CRO Services
Participate In a Study
About Us
Careers
Contact
FR
CRO Services
Participate In a Study
About Us
Careers
Contact
FR
Test
Post navigation
Dupilumab Provides Favorable Safety and Sustained Efficacy for Up to 3 Years in an Open-Label Study of Adults With Moderate-to-Severe Atopic Dermatitis
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
